2016 Judges

The World ADC Awards Judges are handpicked for their longstanding familiarity and deep knowledge of the ADC field.

bob-lutz

Robert Lutz

Robert was at ImmunoGen for 23 years, most recently as VP of Translational Research and Development. He was project lead for numerous proprietary ADCs and a joint research/development committee member with ImmunoGen’s many alliance partners.  In 2015 he began his own consultancy practice, Crescendo BioPharma Consulting, providing strategic, tactical and operational expertise to help meet the needs of emerging biotechnology and pharmaceutical companies worldwide.

 

brian

 

 

 

Brian Clark

Brian Clark is Principal at GMP Operations Consulting and provides interim executive leadership, CMC strategy, manufacturing strategy and operational support to biopharmaceutical companies in the US, Australia and Asia.  Previously, Brian was at ImmunoGen Inc. from 2011 to 2016, most recently serving VP Manufacturing and Norwood Site Head and initially as Executive Director, Quality.  Prior to joining ImmunoGen, Brian was an individual consultant for several years in his current practice.  Brian previously served in senior operations and development leadership roles at Altus Pharmaceutical, Alkermes, Therion Biologics, Antigenics (now Agenus) and Genzyme Tissue Repair.  Brian obtained his MBA in General Management and Entrepreneurship from Boston University and his BS in Biology from the University of Massachusetts.

jagath

 

 

 

 

 

 

 

Jagath Reddy Junutula

Jagath Reddy Junutula, PhD joined Cellerant in April 2014 as a Vice President, Antibody Discovery & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers. He developed a novel THIOMAB technology platform to generate site-specific antibody-drug conjugates (ADCs) to improve the therapeutic utility of antibodies. This technology has widely been accepted as a new standard for the development of therapeutic ADCs. He obtained his PhD in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University. Jagath has authored 60 peer-reviewed publications/patents and has presented his work at numerous international conferences. Jagath serves as an editorial board member of leading antibody therapeutics journal, mAbs.v